Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)

This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.

  • 0 views
  • 21 Jul, 2022
  • 1 location
A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)

intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. Dosing will start in subjects with HGTa or CIS (including CIS with concomitant Ta) NMIBC to include a minimum of 1

  • 0 views
  • 14 Sep, 2022
  • 4 locations
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.

  • 114 views
  • 10 Aug, 2022
  • 10 locations
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

) undergoing treatment with Intravesical BCG. BCG is a weakened form of the bacterium Mycobacterium bovis that does not cause disease. It is used in a solution to stimulate the immune system in the treatment

  • 0 views
  • 17 Jun, 2022
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

hysterectomy
bladder cancer
carcinoma in situ
gemcitabine
carcinoma
  • 2 views
  • 17 Sep, 2021
  • 1 location
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer

bladder cancer
carcinoma in situ
carcinoma
invasive bladder cancer
cancer
  • 290 views
  • 30 Jun, 2022
  • 15 locations
Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial (BCG+MM)

Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. The study aim is to compare disease-free survival between treatment arms: BCG alone versus Mitomycin in addition to BCG.

bladder cancer
cystoscopy
carcinoma in situ
carcinoma
invasive bladder cancer
  • 16 views
  • 15 Sep, 2022
  • 14 locations
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Current treatment of localized muscle-invasive bladder cancer is still associated with high relapse and death rate as well as the need for complete bladder resection or irradiation. The primary objective of this trial is to increase the rate of pathologic complete remission (pCR) at the time of radical cystectomy by …

bladder instillation
radical cystectomy
gemcitabine
cisplatin/gemcitabine
carcinoma
  • 0 views
  • 13 Jul, 2022
  • 9 locations
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective and are seeking an alternative treatment option to radical …

radical cystectomy
bladder cancer
carcinoma in situ
carcinoma
metastasis
  • 19 views
  • 25 Jul, 2022
  • 7 locations
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Gu(SqrRoot)(Copyright)Rin (BCG)

Background Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells. Objective To test if the drugs Durvalumab and Vicineum together are safe and effective to treat people with bladder …

bladder cancer
cystoscopy
carcinoma
durvalumab
invasive bladder cancer
  • 257 views
  • 17 Sep, 2022
  • 1 location